Generic Name and Formulations:
Tafluprost 0.0015%; oph soln; preservative-free.
Indications for ZIOPTAN:
For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
1 drop in conjunctival sac of affected eye(s) once daily in the PM.
Do not exceed recommended dose (may reduce efficacy). Active intraocular inflammation (eg, iritis/uveitis). Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Pregnancy (Cat.C); use effective contraception. Nursing mothers.
Allow at least 5 minutes between application of other topical oph agents.
Conjunctival hyperemia, ocular stinging/irritation, ocular pruritus including allergic conjunctivitis, cataract, dry eye, ocular pain, increased ocular pigmentation (eg, iris, eyelid, eyelashes; may be permanent), other eyelash changes, blurred vision, macular edema, headache, cold, cough, urinary tract infection.
Single-use containers (0.3mL)—30, 90
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL